Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

This phase 1b open-label study assesses the efficacy and safety of avelumab, an anti–programmed death ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer.

http://bit.ly/2RNTznl